CIRM Funded Clinical Trials

Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma


Matthew Spear
Disease Area: 
Multiple Myeloma
Investigator:
CIRM Grant:
CLIN2-10395 (Pre-Active)
Award Value:
$19,813,407
Trial Sponsor:
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
40
ClinicalTrials.gov ID:
Details: 

Poseida Therapeutics is testing the safety of a gene modified cell therapy to treat multiple myeloma, the abnormal growth of malignant plasma cells of the immune system. The company’s technology is seeking to destroy these cancerous myeloma cells with an immunotherapy approach that uses the patient’s own engineered immune system T cells to seek and destroy the myeloma cells. 

Design: 

This is a Phase 1, open-label, multi-center study.

Goal: 

Safety and Efficacy.